Challenges and opportunities for medical directors in pathology and laboratory medicine: Standardization, integration, and innovation

American Journal of Clinical Pathology

Volumn 133, Issue 1, 2010, Pages 8-13

  Hernandez, James S ^a   Dale, Jane C ^a   Bennet, Kevin E ^a   Varkey, Prathibha ^a  

^a MAYO CLINIC   (United States)

Author keywords

Innovation; Integration; Laboratory medicine; Medical directors; Pathology; Standardization

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADMINISTRATIVE PERSONNEL; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MEDICAL PRACTICE; MEDICAL SERVICE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

CHEMISTRY, CLINICAL; DIFFUSION OF INNOVATION; HUMANS; LABORATORIES; PATHOLOGY; PHYSICIAN EXECUTIVES; REAGENT KITS, DIAGNOSTIC; SYSTEMS INTEGRATION;

EID: 73949100085     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPSB4AL5EHAWTC     Document Type: Review

References (17)

1. Hernandez JS. Cost-effectiveness of laboratory testing. Arch Pathol Lab Med. 2003;127:440-445.
2. Friedberg RC, Rauch CA. The role of the medical laboratory director. Clin Lab Med. 2007;27:719-731.
3. Guidi GC, Lippi G, Solero GP, et al. Managing transferability of laboratory data. Clin Chim Acta. 2006;374:57-62.
4. Klee GG, Schryver PG, Kisabeth RM. Analytic bias specifications based on the analysis of effects on performance of medical guidelines. Scand J Clin Lab Invest. 1999;59:509-512.
5. Link RE, Shariat SF, Nyugen CV, et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol. 2004;171(6 pt 1):2234-2238.
6. American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park). 2000;14:267-272, 277-278, 280 passim.
7. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152(6 pt 1):2037-2042.
8. Holmes EW, Erşahin C, Augustine GJ, et al. Analytic bias among certified methods for the measurement of hemoglobin A1c: a cause for concern? Am J Clin Pathol. 2008;129:540-547.
9. An overview of the College of American Pathologists Cancer Checklists. Northfield, IL: College of American Pathologists; 2009. http://www.cap.org/apps/ docs/committees/cancer/cancer-protocols/Overview-CAP-Cancer-Checlkists[ sic]-090115.pdf. Accessed November 17, 2009.
10. Compass Group makes its case for lab's value. CAP Today. May 2008. http://www.cap.org/apps/cap.portal?-nfpb=true&cntvwrPtlt-actionOverride= %2Fportlets%2FcontentViewer%2Fshow&-windowLabel=cntvwrPtlt& cntvwrPtlt%7BactionForm.contentReference%7D=cap- today%2Ffeature-stories%2F0508- Compass-Group.html&-state=maximized&-pageLabel=cntvwr. Accessed November 17, 2009.
11. Hernandez JS, Newton NC, O'Hara SK. Integration and standardization within the Mayo Foundation Laboratories: the centralized laboratory purchasing group. Clin Leadersh Manag Rev. 2005;19:E2.
12. Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics. 2005;2:337-348.
13. Montalto MC. Pathology RE-imagined: the history of digital radiology and the future of anatomic pathology. Arch Pathol Lab Med. 2008;132:764-765.
14. Varkey P, Horne A, Bennet KE. Innovation in health care: a primer. Am J Med Qual. 2008;23:382-388.
15. Moore GA. Darwin and the demon: innovating within established enterprises. Harvard Bus Rev. 2004;82:86-92, 187.
16. Harvard Business Essentials. Managing Creativity and Innovation. Boston, MA: Harvard Business School Publishing; 2003.
17. O'Reilly CA III, Tushman ML. The ambidextrous organization. Harvard Bus Rev. 2004;82:74-81,140.